Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
New Therapy on the Horizon for ALK+ Non-small Cell Lung Cancer: Research | |
|
| |
Discovery of a new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinibthe only approved ALK inhibitor. The presentation of the results of this Novartis-sponsored study will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.
The compound LDK378, developed by Novartis, targets ALKa key cancer gene in a subset of lung cancer, lymphoma and the childhood cancer neuroblastoma, and may be associated with other cancers, including breast and colorectal cancer. The study's authors looked at patients with ALK+ lung cancer, as well as other ALK+ solid tumors. Early data from the phase I study show that the majority of patients treated with active doses of LDK378 responded, including those who had progressed after treatment with crizotinib.
"These results are encouraging," says study author Ranee Mehra, M.D., assistant professor and medical oncologist at Fox Chase. "They offer hope to patients who have tumors with alterations involving ALK, even if they have relapsed from previous treatments.
In its first test in people, designed to determine the compound's safety and optimal dose, 56 people with various types of ALK+ solid tumors (primarily lung cancer) were enrolled, receiving doses between 50 to 750 milligrams per day (mg/day). LDK378 was well-tolerated in most patients up to 750 mg/d, with the most common side effects being nausea, vomiting, and diarrhea.
"Whenever you do a trial with a drug, even if it's just designed to look for safety and dosage, you are interested in whether patients responded," says Mehra. "These results are definitely encouraging, and mean we can go forward with additional research looking at whether LDK378 is effective in various types of cancers that have alterations involving ALK."
The fact that patients appeared to tolerate LDK378 at doses up to 750 mg/d is also encouraging, she adds, since preclinical research has suggested this dose would have therapeutic effects.
In the meantime, Mehra and investigators at other centers around the world are continuing to enroll patients in the trial. The next phase of the study will test the maximum tolerated dose of LDK378 in all patients enrolled.
Source-Eurekalert
| |
|
|
More News on: Parkinsons Disease Surgical Treatment, Reiki and Pranic Healing, Cystic Fibrosis, Pneumoconiosis, Silicosis
 Comment & Contribute
|
Related Links
Lung Cancer
Lung cancer is the uncontrolled growth of abnormal cells in the lung. Majority of people who get lung cancer have been cigarette smokers, but not all ...
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible ...
Health Hazards of Smoking Cigarettes
Information on the Health Hazards of Smoking Cigarettes, and its effect on Blood Pressure, and general health. ...
Cancer Related News
Link Between Agent Orange Exposure and Prostate Cancer
A new study has now linked the exposure to Agent Orange and lethal forms of prostate cancer among the US Veterans. Published early online in ...
Tumour Growth Mechanism Goes a Step Further
New study suggests that loss of a particular tumour-suppressing protein causes abnormal growth of tumours of the brain and nervous system. ...
Link Between Skin Cancer and Lower Risk of Alzheimer's Disease Identified
According to a recent study people who have skin cancer are at a reduced risk of developing Alzheimer's disease. The link does not apply to melanoma, ...
Molecular Profiling Timely for Tailoring Therapy Shown By First Prospective Trial
Patients, and their physicians, are eager to jump into next-era cancer care analysis of an individual's tumor to find and target genetic mutations ...
Broad Support for Rationing of Some Types of Cancer Care Found By Penn Medicine Study
According to results, the majority of cancer doctors, patients, and members of the general public support cutting health care costs by refusing to ...
Study Finds Women in 40s Continue to Undergo Routine Mammograms Despite New Recommendations
Researchers at Johns Hopkins found that despite new national guidelines, women in their 40s continued to undergo routine breast cancer screening. ...
- Health News Index
|
|
 | Quiz on Cancer Looking for information on cancer? Go through medindia's Cancer quiz. 
|
- News Quick Links
 |
Cancer
Complete Medindia Resources
|
| News Categories: |
| » | Hospital Use and Costs Not Increased by Massachusetts' Health Care Reform |
| » | Preparation on for Health Care Revamping |
| » | Federal Spending to Treat Chronic Pain Should be a Top Healthcare Priority |
| » | Obama Campaigns to Advance Health Care Program |
| » | Quality Improvement Platform can Help Improve Patient Outcomes |
| More Insurance News | |
|
Ask an Expert
